Dangers Yaz Imposed by Big Pharma
Studies performed on healthy, premenopausal women in the Netherlands specified that Yaz, Yasmin, and Ocella (Yasmin generic) suffered an raised risk of venous thrombosis as compared to non-users. The risks were increased as high as five times with oral contraceptive pills. These studies were published in August 2009. This was only the beginning of the contention surrounding Yaz, Yasmin, and Ocella and the consequent lawsuits to come involving Yaz side effects.
Among the other arguments surrounding Yasmin, Yaz and Ocella birth control, the drugs also contain drospirenone, an element not in other oral contraceptives. The British Medical Journal released studies in August 2009 exhibiting an increased risk of venous blood clots in women taking drospirenone as opposed to those who received other oral contraceptives. In that same month, the FDA issued an uncorrelated warning letter to Bayer Pharmaceuticals, makers of Yasmin, for using low-quality batches of drospirenone from a plant in Germany. For the benefit of public interest and well-being, these studies have been made available free on the web.
Adult Females taking Yasmin, Yaz or Ocella to avoid getting pregnant or to treat PMDD (Premenstrual Dysphoric Disorder) or severe acne have reportedly endured major injury to their health and wellness. Although most pharmaceuticals present some form of side effects, the main issue surrounding Yaz seems to be that the original commercials downplayed the health risks and side effects. This attracted users to the product that may not have taken it otherwise had they been properly informed about the risks posed by Ocella, Yasmin and Yaz.
Tags:blood clot, Blood Clot Related Injury, Cardiovascular Injury, Cerebral Venous Sinus Thrombosis, deep vein thrombosis, DVT, Heart Attack, Heart Arrhy, PE, pulmonary embolism, yasmin birth control side effects, yasmin side effects, yaz side effects, yaz/yasmin lawsuit